Faure, Léa
Noize, Pernelle
Couchoud, Cécile
Hucteau, Emilie
Berdougo, Jessica
Guerville, Florent
Harambat, Jerome
Combe, Christian
Levassort, Hélène
Moranne, Olivier
Hamroun, Aghilès
Beuscart, Jean-Baptiste
Leffondré, Karen
Prezelin-Reydit, Mathilde
,
Funding for this research was provided by:
French National Agency for Medicines and Health Products Safety (EPI-PHARE call for proposals no. 2022S058/EC 2022-05)
French Biomedicine Agency
Article History
Received: 3 September 2025
Accepted: 30 January 2026
First Online: 11 March 2026
Declarations
:
: The REIN registry was approved by the relevant French committees, the Comité consultatif sur le traitement de l’information en matière de recherché (CCTIRS N°03–149) and the Commission nationale de l’informatique et des libertés (CNIL N° 903188). For population-based registries requiring exhaustiveness, French regulations require that patients be informed by the clinic that they can choose not to participate (opt-out). Patients’ information have been anonymized and de-identified before the extraction for analysis. Access to the databases used in the present study was obtained from the REIN scientific committee and the CCTIRS (N°15–1046) and CNIL (N° 916072). No consent to participate was required due to the retrospective nature of this study.
: Not applicable.
: The authors declare no competing interests.